Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age

Vaccine

Volumn 18, Issue 27, 2000, Pages 3134-3140

  Klinge, J ^a   Lugauer, S ^a   Korn, K ^a   Heininger, U ^a   Stehr, K ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Immunisation age; Measles; Mumps; Rubella immunisation; Seroconversion rate

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; MMRVAX; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; FEVER; GERMANY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; MEASLES; MULTICENTER STUDY; MUMPS; PAIN; PHARYNGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RHINITIS; RUBELLA; SEROCONVERSION;

AGE FACTORS; ANTIBODIES, VIRAL; FEVER; HUMANS; INFANT; MEASLES VACCINE; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS VACCINE; RUBELLA VACCINE; VACCINATION; VACCINES, COMBINED;

EID: 0034662393     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00096-7     Document Type: Article

References (26)

1. Albrecht P., Ennis F.A., Saltzman E.J., Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91:1977;715-718.
2. Balfour H.H., Amren D.P. Rubella, measles and mumps antibodies following immunisation in children. Am. J. Dis. Child. 132:1978;573-577.
3. Krugman R.D., Rosenberg R., McIntosh K., Herrmann K., Witte J.J., Ennis F.A., Meyer B.C. Further attenuated live measles vaccines: The need for revised recommendations. J. Pediatr. 91:1977;766.
4. Shasby D.M., Shopfe T.C., Downs H., Herrmann K.L., Polkowski J. Epidemic measles in a highly vaccinated population. N. Engl. J. Med. 296:1978;585-589.
5. Shelton J.D., Jacobson J.E., Orenstein W.A., Schulz K.F., Donnell H.D. Measles vaccine efficacy: influence of age at immunisation vs. duration of time since immunisation. Pediatrics. 62:1978;961-964.
6. Wilkins J., Wehrle P.F. Additional evidence against measles vaccine administration to infants less than 12 months of age: altered immune response following active and passive immunisation. J. Pediatr. 94:1979;865-869.
7. Krugman S., Giles J.P., Friedman H., Stone S. Studies on immunity to measles. J. Pediatr. 66:1965;471-488.
8. Lennon J.L., Black F.L. Maternally derived measles immunity in the era of vaccine-protected mothers. J. Pediatr. 108:1986;671-676.
9. Brugha R., Ramsay M., Forsey T., Brown D. A study of maternally derived measles antibody in infants born to naturally infected or vaccinated women. Epidemiol. Infect. 117:1996;519-524.
10. Brystriakova L.V., Zaitseva R.V., Kolobova L.V., Pushkareva E.A., Smorodinova I.P. Transplacental measles immunity in infants in the 1st year of life. Zh. Mikrobiol. Epidemiol. Immunbiol. 10:1991;50-52.
11. De Serres G., Joly J.R., Fauvel M., Meyer F., Masse B., Boulianne N. Passive immunity against measles during the first 8 months of life of infants born to vaccinated mothers or to mothers who sustained measles. Vaccine. 15:1997;620-623.
12. Maldonado Y.A., Lawrence E.C., DeHovitz R., Hartzell H., Albrecht P. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics. 96:1995;447-450.
13. Markowitz L.E., Albrecht P., Rhodes P., Demonteverde R., Swint E., Maes E.F., Powell C., Patriarca P.A. The Kaiser permanente measles vaccine trial team. Changing levels of measles antibody titers in women and children in the United States: Impact on responses to immunisation. Pediatrics. 97:1996;53-58.
14. Pabst H.F., Spady D.W., Marusyk R.G., Carson M.M., Chui L.W., Joffres M.R., Grimsrud K.M. Reduced measles immunity in infants in a well-vaccinated population. Pediatr. Infect. Dis. J. 11:1992;525-529.
15. Singh R., John T.J., Cherian T., Raghupathy P. Immune reponse to measles, mumps & rubella vaccine at 9, 12 & 15 months of age. Indian J. Med. Res. 100:1994;155-159.
16. Bolotovski V.M., Grabowsky M., Clements C.J., Albrecht P., Brenner E.R., Zargaryants A.I., Litvinov S.K., Mikheyeva I.V. Immunisation of 6 and 9 month old infants with AIK-C, Edmonton-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine. Int. J Epidemiol. 23:1994;1069-1077.
17. Forleo-Neto E., Carvalho E.S., Fuentes I.C., Precivale M.S., Forleo L.H., Farhat C.K. Seroconversion of a trivalent measles, mumps and rubella vaccine in children aged 9 and 15 months. Vaccine. 15:1997;1898-1901.
18. Johnson C.E., Nalin D.R., Chui L.W., Whitwell J., Marsyk R.G., Kumar M.L. Measles vaccine immunogenicity in 6- versus 15-month old infants born to mothers in the measles vaccine era. Pediatrics. 93:1994;939-943.
19. Recommended childhood immunisation schedule: United States, January 1995. Morbid. Mortal. Wkly. Rep. 43:1995;959-960.
20. Klinge J., Korn K., Heininger U. Stehr K. Prävakzinale Antikörper gegen Masen, Mumps- und Rötelnviren im Säuglings- und frühen Kleinkindesalter. Monatsschr. Kinderheilkd. 144:1996;825-829.
21. Gans H.A., Arvin A.M., Galinus J., Logan L., DeHovitz R., Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA. 280:1998;527-532.
22. STIKO. Impfempfehlungen der Ständigen Impfkommission (STIKO), Stand März 1997.Epidemiologisches Bulletin 1997;15/97: pp. 97-108.
23. Carson M.M., Spady D.W., Albrecht P., Beeler J.A., Thipphawong J., Barreto L., Grimsrud K.M., Pabst H. Measles immunisation of infants in a well-vaccinated population. Pediatr. Infect. Dis. J. 14:1995;17-22.
24. Dagan R., Slater P.E., Duvdevani P., Golubev N., Mendelson E. Decay of maternally derived measles antibody in a highly vaccinated population in southern Israel. Pediatr. Infect. Dis. J. 14:1995;965-969.
25. De Serres G., Boulianne N., Ratnam S., Corriveau A. Effectiveness of immunisation at 6-11 months of age during an outbreak of measles. Pediatrics. 97:1996;232-235.
26. Shinefield H.R., Black S.B., Staehle B.O., Adelman T., Ensor K., Ngai A., White C.J., Bird S.R., Matthews H., Kuter B.J. Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX. Pediatr. Infect. Dis. J. 17:1998;980-985.